Yahoo Web Search

Search results

    • AbbVie makes oncology progress with two drug trials

      Crain s Chicago Business· 16 hours ago

      Multiple myeloma, the second-most common blood cancer, is characterized by abnormal proliferation of plasma cells, which can cause end-organ damage, AbbVie said in a statement. The start of ...